Mechanistically distinct chemotherapeutics cause CIPN via Sarm1

Previous work by Dr. Stefanie Geisler had shown that axonal damage subsequent to administration of vincristine, a common chemotherapeutic, was a result of a Sarm1-dependent mechanism. In the recent JCI Insight paper titled “Vincristine and bortezomib use distinct upstream mechanisms to activate a common SARM1-dependent axon degeneration program,” Dr. Geisler and colleagues demonstrated that Bortezomib, a chemotherapeutic with a very different mechanism of action than vincristine’s, also triggers the Sarm1-dependent axonal degeneration program.

Leave a Reply

Your email address will not be published. Required fields are marked *